JF

30

Aug2019

CADTH Releases Pharmaceutical Reviews Update 10

CADTH’s Pharmaceutical Reviews Updates are used to communicate new CDR and pCODR drug review processes updates to the public. PDCI has outlined below the key highlights from the most recent update. For more information on this review, please consult the CADTH website. CADTH has extended the ... Read More

27

Aug2019

UPCOMING WEBINAR SEPTEMBER 4: 2019 PMPRB Regulation Amendments and Implications

PDCI and 3Sixty Public Affairs invites its industry clients, partners and colleagues to participate in a webinar on September 4, 2019 between 2:00pm to 3:00pm. This important session will cover the PMPRB price regulatory amendments and share insights on their implications for pharmaceutical market access. The session will provide an overview of ... Read More

19

Aug2019

HDAP 2020 Meeting Dates Released

The PMPRB has announced the 2020 meeting dates to the Human Drug Advisory Panel (HDAP)’s , releasing a total of four (4) dates, as per previous years. This corrected version of TargetPharma makes a distinction between the deadline for submitting the Product Monograph and the deadline for the Patentee's submission.... Read More

12

Aug2019

Status Summary of Innovative Medicine pCPA Negotiations as of July 31, 2019

Each month the pCPA issues an update on the previous month’s negotiation activity. Below, you will find an overview of the new pCPA activity along with PDCI insights into recent developments for your interest. Summary of New pCPA Activity ... Read More

09

Aug2019

HEALTH CANADA AMENDMENTS TO PMPRB REGULATIONS

PMPRB and Health Canada held two technical briefings on the soon-to-be published final amendments to the Patented Medicines Regulations (PMR) on August 9th, 2019. This coincided with the pre-release of the final regulatory text and an updated Regulatory Impact Analysis Statement (RIAS). Publication in Canada Gazette II is expected August ... Read More

08

Aug2019

CADTH Releases Pharmaceutical Reviews Update Issue 9

CADTH’s Pharmaceutical Reviews Updates are used to communicate new CDR and pCODR drug review processes updates to the public. PDCI has outlined below the key highlights from the most recent update. For more information on this review, please consult the CADTH’s website. CADTH has three new consultations ... Read More

08

Jul2019

Status Summary of Innovative Medicine pCPA Negotiations as of June 30, 2019

Each month the pCPA issues an update on the previous month’s negotiation activity. Below you will find an overview of the new pCPA activity along with PDCI insights into recent developments for your interest. Summary of New pCPA Activity Since Last Update Category New File... Read More

04

Jul2019

PDCI Announces Strategic Partnership with Goeree Consulting Ltd.

PDCI Market Access Inc. is pleased to announce a new Strategic Partnership with Goeree Consulting Ltd (owned and operated by Ron Goeree). Goeree Consulting and PDCI are bringing together an exceptional level of experience and expertise in health economics, while further expanding ... Read More

19

Jun2019

Status Summary of Innovative Medicine pCPA Negotiations as of May 31, 2019

Each month the pCPA issues an update on the previous month’s negotiation activity. In the summary below you will find an overview of the new pCPA activity along with PDCI insights into recent developments for your information. Summary of New pCPA Activity Since Last Update... Read More

18

Jun2019

PMPRB Announces New Board Vice-Chairperson

Effective June 14, 2019, Mélanie Bourassa Forcier is Vice-Chairperson of the Patented Medicine Prices Review Board (PMPRB)    Professor Bourassa Forcier is an Associate Professor in the Faculty of Law at the Université de Sherbrooke, and directs the Law and Health Policy, and Law and Life Sciences programs. ... Read More